Outcomes of patients treated with SVILE vs.P-GemOx for extranodal natural killer/T-cell lymphoma,nasal type:a prospective,randomized controlled study

作     者：Liqiang Wei Lei Yang Jin Ye Jia Cong Xin Li Na Yao Jing Yang Xueying Cui Jing Ding Yiping Wu Jingwen Wang Liqiang Wei;Lei Yang;Jin Ye;Jia Cong;Xin Li;Na Yao;Jing Yang;Xueying Cui;Jing Ding;Yiping Wu;Jingwen Wang

作者机构：Department of HematologyBeijing Tongren HospitalCapital Medical UniversityBeijing 100730China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2020年第17卷第3期

页      面：795-804页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This study was supported by grants from Beijing Municipal Science&Technology Commission(Grant No.Z151100004015089) 

主　　题：Extranodal natural killer/T-cell lymphoma nasal type chemotherapy overall response radiotherapy 

摘      要：Objective:To compare the efficacy and safety of the novel SVILE regimen with the P-GemOx regimen in patients with newly diagnosed extranodal natural killer/T-cell lymphoma,nasal type(ND-ENKTL).Methods:From April 2015 to July 2018,103 patients with ND-ENKTL were randomly assigned to SVILE(experimental group)or P-GemOx(control group)chemotherapy followed by radiotherapy and consolidation *** primary endpoint was the overall response rate after 3 cycles of chemotherapy,and secondary study endpoints were complete response(CR),progression-free survival(PFS),and overall survival(OS).Safety was also ***:There were no significant differences in baseline characteristics in the *** *** experimental and control groups,respectively,the overall response rates were 91.7%vs.97.0%for stageI/II and 75.0%vs.72.2%for stage III/*** CR rates were 83.4%vs.97.0%for stage I/II and 68.8%vs.61.1%for stage III/*** of those differences were *** was no significant difference in PFS and OS between groups and between patients in stage I/II and stage III/*** 3-year PFS and OS in stage I/II were 88.3%vs.93.3%and 88.8%vs.97.0%,*** 3-year PFS and OS in stage III/IV were 46.2%vs.65.7%and 68.8%vs.72.2%,*** common adverse events were hematological toxicity,hepatotoxicity,and coagulation abnormalities,which were found to be reversible with supportive ***:The novel SVILE regimen has comparable effects to those of P-GemOx in patients with ND-ENKTL and is well *** is a therapeutic option for ND-ENKTL.